These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 8156540)

  • 1. Adoptive cellular therapy of urological neoplastic disease.
    Gold JE; Osband ME; Krane RJ
    Cancer Treat Rev; 1994 Apr; 20(2):173-90. PubMed ID: 8156540
    [No Abstract]   [Full Text] [Related]  

  • 2. [Biological response modifiers and urological cancer].
    Ohmori H; Tazaki H
    Nihon Hinyokika Gakkai Zasshi; 1992 Jun; 83(6):850-6. PubMed ID: 1501395
    [No Abstract]   [Full Text] [Related]  

  • 3. Cellular therapy: scientific rationale and clinical results in the treatment of metastatic renal-cell carcinoma.
    Pierce WC; Belldegrun A; Figlin RA
    Semin Oncol; 1995 Feb; 22(1):74-80. PubMed ID: 7855622
    [No Abstract]   [Full Text] [Related]  

  • 4. [Cell therapy in renal cell carcinoma].
    Ravaud A
    Bull Cancer; 2003; 90(8-9):711-21. PubMed ID: 14609761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adoptive immunotherapy of urologic tumors.
    Belldegrun A; Rosenberg SA
    Cancer Treat Res; 1989; 46():213-33. PubMed ID: 2577191
    [No Abstract]   [Full Text] [Related]  

  • 6. Adoptive cellular therapy.
    Sznol M; Urba WJ
    Cancer Chemother Biol Response Modif; 1991; 12():213-30. PubMed ID: 1931444
    [No Abstract]   [Full Text] [Related]  

  • 7. Adoptive immunotherapy of renal cell carcinoma: studies from the Surgery Branch, National Cancer Institute.
    Linehan WM; Walther MM; Alexander RB; Rosenberg SA
    Semin Urol; 1993 Feb; 11(1):41-3. PubMed ID: 8465127
    [No Abstract]   [Full Text] [Related]  

  • 8. [Cell therapy for renal cell carcinoma].
    Kawai K
    Gan To Kagaku Ryoho; 2002 Oct; 29(10):1745-51. PubMed ID: 12402424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Immunotherapy and urological malignancy].
    Marumo K
    Nihon Hinyokika Gakkai Zasshi; 1991 Mar; 82(3):361-71. PubMed ID: 1712869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adoptive immunotherapy with recombinant interleukin 2, LAK and TIL.
    Kurnick JT; Kradin RL
    Allergol Immunopathol (Madr); 1991; 19(5):209-14. PubMed ID: 1811418
    [No Abstract]   [Full Text] [Related]  

  • 11. [Study on adoptive immunotherapy in patients with renal cell carcinoma. II. Plasmapheresis with adoptive immunotherapy using LAK cells and IL-2].
    Usui A
    Nihon Hinyokika Gakkai Zasshi; 1990 Jul; 81(7):1058-64. PubMed ID: 2214469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Generation and activation of tumor-infiltrating lymphocytes (TIL) within the scope of lymphokine activated killer cell therapy (LAK-TIL therapy) in patients with advanced breast and ovarian carcinoma].
    Mallmann P; Krebs D
    Gynakol Geburtshilfliche Rundsch; 1995; 35 Suppl 1():161-5. PubMed ID: 8672919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adoptive immunotherapy of patients with metastatic renal cell cancer using lymphokine-activated killer cells, interleukin-2 and cyclophosphamide: long-term results.
    Tomita Y; Katagiri A; Saito K; Imai T; Saito T; Tanikawa T; Terunuma M; Nishiyama T; Takahashi K
    Int J Urol; 1998 Jan; 5(1):16-21. PubMed ID: 9535595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer immunotherapy using tumor-infiltrating lymphocytes.
    Figlin RA
    Semin Hematol; 1992 Apr; 29(2 Suppl 1):33-5. PubMed ID: 1535456
    [No Abstract]   [Full Text] [Related]  

  • 15. Autologous activated lymphocyte therapy in a community hospital.
    Horváth J; Szabó-Szabari M; Sinkovics JG
    Acta Microbiol Immunol Hung; 1994; 41(2):205-14. PubMed ID: 7804724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Lymphokine-activated killer cell adoptive immunotherapy for cancer treatment and its significance].
    Toge T; Yamaguchi Y
    Hum Cell; 1992 Sep; 5(3):218-25. PubMed ID: 1334695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Adoptive immunotherapy in patients with multiple hepatic cancers using lymphokine activated killer cells (LAK) and interleukin-2].
    Kanai T; Monden M; Takeda T; Gotoh M; Sakon M; Umeshita K; Hasuike Y; Sakita I; Nakano H; Yoshida T
    Gan To Kagaku Ryoho; 1993 Aug; 20(11):1457-60. PubMed ID: 8396896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cellular immunotherapy of cancer].
    Kawakami Y
    Rinsho Ketsueki; 2003 Jun; 44(6):358-67. PubMed ID: 12884813
    [No Abstract]   [Full Text] [Related]  

  • 19. [Study of adoptive immunotherapy for metastatic renal cell carcinoma with lymphokine-activated killer (LAK) cells and interleukin-2. II. Clinical evaluation].
    Nomura K; Fujioka T
    Nihon Hinyokika Gakkai Zasshi; 1993 May; 84(5):831-40. PubMed ID: 8320888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin-2 immunotherapy followed by resection of residual renal cell carcinoma.
    Fleischmann JD; Kim B
    J Urol; 1991 May; 145(5):938-41. PubMed ID: 2016805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.